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Abstract
This study is aimed at elucidating the structure of a novel T-cell adhesion inhibitor, cyclo(1,8)-
CPRGGSVC using one- and two-dimensional 1H NMR and molecular dynamics (MD) simulation.
The peptide is derived from the sequence of its parent peptide cIBR (cyclo(1,12)-
PenPRGGSVLVTGC), which is a fragment of intercellular adhesion molecule-1 (ICAM-1). Our
previous results show that the cyclo(1,8)-CPRGGSVC peptide binds to the LFA-1 I-domain and
inhibits heterotypic T-cell adhesion, presumably by blocking the LFA-1/ICAM-1 interactions. The
structure of the peptide was determined using NMR and MD simulation in aqueous solution. Our
results indicate that the peptide adopts type-I β-turn conformation at the Pro2-Arg3-Gly4-Gly5
(PRGG) sequence. The β-turn structure at the PRGG motif is well conserved in cIBR peptide and
ICAM-1 receptor, which suggests the importance of the PRGG motif for the biological activity of
cyclo(1,8)-CPRGGSVC peptide. Meanwhile, the Gly5-Ser6-Val7-Cys8-Cys1 (GSVCC) sequence
forms a “turn-like” random coil structure that does not belong to any structured motif. Therefore,
cyclo(1,8)-CPRGGSVC peptide has only one structured region at the PRGG sequence, which may
play an important role in the binding of the peptide to the LFA-1 I-domain. The conserved β-turn
conformation of the PRGG motif in ICAM-1, cIBR, and cyclo(1,8)-CPRGGSVC peptides can
potentially be used to design peptidomimetics.
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INTRODUCTION
Human immune response is activated when thymus-derived lymphocyte (T cell) contacts an
antigen-presenting cell (APC) by forming an immunological synapse.1–3 This contact zone
consists of two signals: a primary signal (Signal-1) that comes from the interaction between
the T-cell receptor (TCR) and antigen-MHC-II complex, and a co-stimulatory signal
(Signal-2) that originates from the attachment of several molecules such as leukocyte
function-associated antigen-1 (LFA-1) and the intercellular adhesion molecule-1 (ICAM-1).
4–6 The formation of an immunological synapse followed by the immune response is
required by the human body as part of its defense mechanism. However, in autoimmune
diseases, it could harm the host body if the T cell recognizes the host's tissue as an antigen.
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Therefore, blocking of formation of the immunological synapse could be significant in
suppressing autoimmune diseases and allograft rejection.
Choosing the right target molecule to block an immune synapse requires a depth of
knowledge of molecular actions during synapse formation. It has been proposed that during
early events of immune synapse formation LFA-1/ICAM-1 complex (Signal-2) is formed at
the center of the T-cell/APC interface. The LFA/ICAM-1 complex forces the outermost ring
of the T-cell membrane to move closer to the APC to enable the formation of TCR-Ag-
MHC complex (Signal-1). This event is followed by translocation of Signal-1 to the center
of the synapse and Signal-2 to the edge of the T-cell/APC interface.3 The mechanism of
immune synapse formation suggests that blocking the LFA-1/ICAM-1 interactions
(Signal-2) could influence the formation of TCR-Ag-MHC complex (Signal-1), thus playing
a significant role in suppressing the autoimmune response.7 In addition to altering the
formation of the immune synapse, blocking of LFA-1/ICAM-1 interactions has also been
shown to alter the immune response via induction of a certain T-cell phenotype (i.e., Th-1 or
Th-2).8
Inhibition of ICAM-1/LFA-1 interactions with monoclonal antibodies to ICAM-1 and
LFA-1 has been shown to suppress allograft rejection9,10 and autoimmune diseases such as
psoriasis,11,12 type-1 diabetes,13 and rheumatoid arthritis.14,15 Besides antibodies, several
small molecules,16,17 peptides,18,19 and peptidomimetics20 have been developed as
inhibitors for LFA-1/ICAM-1 interactions. Our group has discovered several LFA-1/
ICAM-1 peptide inhibitors derived from the sequences of LFA-1 and ICAM-1.19 One of the
peptides, called cIBR (cyclo(1,12)-PenPRGGSVLVTGC), has been shown to inhibit
homotypic and heterotypic adhesion of T cells.21,22 This peptide has also been shown to
bind to the I-domain of LFA-1 receptor on MIDAS and L-site.23,24
The solution structure of cIBR peptide showed that the Pro2-Arg3-Gly4-Gly5 (PRGG)
region forms a β-turn structure that mimics the conformation of the same region on its parent
ICAM-1 molecule.25 It has been shown that turn motifs are usually present on the surface of
proteins and are likely involved in the protein-protein interactions.26 Our initial results
indicated that the PRGG motif in cIBR peptide is important for the biological activity of the
peptide.22 Then, we synthesized several fragments of cIBR peptide by reducing the size of
the peptide from the C-terminus. We found that the shorter derivative of cIBR peptide,
namely, cyclo(1,8)-CPRGGSVC peptide, showed better activity than other cIBR derivatives,
even slightly better than its parent cIBR peptide.27 The smaller size of cyclo(1,8)-
CPRGGSVC and its lower hydrophobicity than its parent peptide (cIBR) potentially enable
this peptide to be conjugated to hydrophobic drugs for targeted drug delivery without
creating highly hydrophobic conjugates as happened to cIBR-Dox.28 The smaller size of
cyclo(1,8)-CPRGGSVC also makes this peptide a good candidate for designing
peptidomimetics.
In this work, we determined the conformation of cyclo(1,8)-CPRGGSVC peptide using one-
dimensional and two-dimensional 1H NMR and molecular dynamics simulation. We found
that the cyclo(1,8)-CPRGGSVC peptide retains only the β-turn conformation at the PRGG
motif; however, it lacks the second β-turn structure found in cIBR peptide. This result
suggests that the PRGG motif and conformation play an important role in the peptide
activity in inhibiting of T-cell adhesion.
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Two-dimensional TOCSY and ROESY spectra were used to assign each proton resonance
and the proton connectivities. The fingerprint region of the TOCSY spectrum shows
through-bond connectivities between amide protons and side chain protons (Figure 1a and
Table 1). The amide proton of Arg3 shows through-bond connectivities to its respective
HCα, HCβ, HCγ, and HCδ. The amide protons of Ser6 and Cys 8 show connectivities to
their respective HCα and HCβ. Both Gly4 and Gly 5 have connectivities between their
amide protons to HCα. Gly4 shows two geminal HCα, while Gly5 shows only one HCα in
the TOCSY spectrum. The amide proton of Val7 has connectivities to its respective HCα,
HCβ, and HCγ. The N-terminal proton of Cys1 cannot be identified due to fast exchange
with water protons. Because Pro2 lacks the amide proton, this residue does not show any
peak in amide proton connectivity.
The two-dimensional ROESY spectrum of the NH-HCα region was used to identify the
sequential connectivities of neighboring residues (Figure 1b). The resonances for Gly4 and
Gly5 were identified by their respective dNα sequential connectivities to Arg3 and Ser6,
respectively. The complete sequential “backbone walk” of all residues in the peptide, which
consists of 12 ROE cross-peaks, including dαN(i, i+1) and dNα(i, i) ROE cross-peaks is: dαN
of Pro2-Arg3 (peak 1), dNα of Arg3 (peak 2), dαN of Arg3-Gly4 (peak 3), dNα of Gly4 (peak
4), dαN of Gly4-Gly5 (peak 5), dNα of Gly5 (peak 6), dαN of Gly5-Ser6 (peak 7), dNα of Ser6
(peak 8), dαN of Ser6-Val7 (peak 9), dNα of Val 7 (peak 10), dαN of Val7-Cys8 (peak 11),
and dNα of Cys8 (peak 12) (Figure 1b). Cys1-Pro2 connectivity was not observed due to fast
exchange of Cys1 amide protons with water.
Chemical Shift Assignments
Because the chemical shift of HCα depends on the backbone dihedral angles (φ and ψ) and
on the local chemical environment, the chemical shift index (CSI), which defines the
difference between the measured chemical shifts and the chemical shifts when the peptide is
in a statistical coil structure, can be used to elucidate the secondary structure adopted by the
peptide.29 The CSI values can be negative (−1) or positive (+1), depending on whether the
measured HCα chemical shift of an amino acid is lower or higher than the HCα chemical
shift of the amino acid in a random-coil chemical. A peptide with a helical structure must
have four or more sequential residues with negative CSI values; β-strand peptides are
indicated by three or more sequential residues with positive CSI values.
In cyclo(1,8)-CPRGGSVC, no four sequential residues have negative SCI values, indicating
that the peptide does not adopt a helical conformation (Figure 2). The possibility of the
peptide adopting β-strand structure can also be ruled out because no three consecutive
residues have positive CSI values. This suggests that the peptide adopts the turn structure or
a random coil. However, the CSI values could not be used to indicate these two structures;
thus, the ROE pattern and 3JNH-HCα scalar coupling constants are needed to determine the
conformation of the peptide.
ROE Pattern and 3JNH-HCα Scalar Coupling Constants
The conformation of cyclo(1,8)-CPRGGSVC peptide was determined by evaluating the
ROE connectivities (Figure 1c) and 3JNH-HCα scalar coupling constant (Figure 3 and Table
2). The possibility of the peptide adopting helical structure could be ruled out because there
were no characteristic ROE cross-peaks from dNN(i, i+1) , dαN(i, i+3), dαN(i, i+4), and dαβ(i,
i+3). In addition, there were no characteristic ROE cross-peaks for β-strand structure, which
are strong dαN(i, i+1) cross-peaks but without dNN(i, i+1). The presence of dNN(i, i+1) and
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dαN(i, i+1) ROE cross-peaks indicates the propensity to adopt a turn structure. Four dNN(i, i
+1) ROE cross peaks were found, i.e. Arg3-Gly4, Gly4-Gly5, Ser6-Val7, and Val7-Cys8
(Figure 1c). The dNN(i, i+1) ROE cross-peak of Gly5-Ser6 was too weak to observe. This
suggests that the peptide has two turns. The first is a type-I β-turn at Pro2-Arg3-Gly4-Gly5
(PRGG), which is supported by the successive dNN(i, i+1) ROE cross-peaks of Arg3-Gly4
and Gly4-Gly5. The dihedral angle (φ) calculated from 3JNH-HCα coupling constants (Table
2) confirms that the PRGG sequence has the propensity to form a type-I β-turn. The
calculated φ of Arg3 (i+1) and Gly4 (i+2) fall within the 30° deviation limit from the ideal φ
for type-I β-turn conformation;26 Arg3 has a calculated φ of −79.46° (ideal φ for type-1 β-
turn is −60°) and Gly4 has a calculated φ of −70.28° compared to the ideal φ of −90°. The
small values of 3JNH-HCα of Arg3 (6.65 Hz), Gly4 (5.48 Hz), and Gly5 (5.67 Hz) also
suggest that the PRGG sequence adopts turn structure (Table 2).
Since we identified Pro2-Arg3-Gly4-Gly5 adopts a type-I β-turn structure, we expected to
see a dαN(i, i+2) ROE cross-peak between Arg3 and Gly5. However, our observation shows
that this dαN(i,i+2) ROE cross-peak is very weak. Our effort to lower the contour level
results in a very complex ROESY spectrum that might cause difficulties for the readers to
see the important dNα(i, i) and dαN(i, i+1) cross-peaks for the sequential “backbone walk”
(Fig. 1b).
The second turn is observed at the Gly5-Ser6-Val7-Cys8 (GSVC) sequence, and the
determination of its turn type is not as straightforward and conclusive as in the PRGG
sequence. The presence of successive dNN(i, i+1) ROE cross-peaks of Ser6-Val7 and Val7-
Cys8 suggests that the GSVC sequence may adopt a type-I β-turn as in the PRGG sequence.
The Ser6 (i+1) has a calculated φ of −89.25° that deviates less than 30° from the ideal φ of
−60°, while Val7 has a calculated φ of −96.98°, close to the ideal value of −90° (Table 1).
The 3JNH-HCα values for GSVC are larger than the values in the PRGG sequence. Only one
residue (Gly5) has 3JNH-HCα value less than 6.0 Hz, while Ser6 has 3JNH-HCα value of 7.83
Hz and Val7 has 3JNH-HCα values larger than 8 Hz (Table 2), suggesting that the GSVC
sequence may not have a classical β-turn structure. Because the determination of GSVC
secondary structure using ROE patterns and 3JNH-HCα scalar coupling constant did not give
a conclusive result, molecular dynamics simulation of the peptide using ROE restraint was
performed to help elucidate the conformation of the GSVC sequence.
Molecular Model of the Peptide Structure
The three-dimensional structure of the peptide was determined by restrained molecular
dynamics (MD) simulation using ROE distance restraints and peptide bond (ω) dihedral
angle restraint of 180 ± 10° to keep all peptide bond as trans, except for Cys1-Pro2 peptide
bond. From the last 500 ps of MD trajectories, all interproton distances are deviated less
than 0.5 Ǻ from the upper boundaries of ROE distance restraints (Table 3). The MD-
simulated φ angles for all residues in the peptide are within 30° of the φ values calculated
from the 3JNH-HCα, except Gly5 that has one φ value outside the 30° deviation limit,
presumably due to the flexibility of this residue (Table 2). Ten structures from the MD
simulation were taken as an ensemble of the peptide structures in solution (Figure 4a).
The presence of a type-I β-turn at the PRGG sequence was confirmed by the φ and ψ angles
from the last 500 ps trajectories of the MD simulation. The average φ and ψ angles of
residues at the PRGG sequence are (φ°, ψ°): Pro2 (−78.0 ± 8.2°, 163.2 ± 6.3°), Arg3 (−88.6
± 7.0°, −24.8 ± 11.25°), Gly4 (−72.1 ± 12.1°, 15.2 ± 13.8°). Gly5 has two sets of φ angles
(−169.6 ± 19.3° and 171.7 ± 6.3°) and ψ angles (−174.7 ± 4.3° and 167.4 ± 8.1°) (Table 2),
which are due to the flexibility of the Gly5 backbone. The simulated and J-coupling
calculated φ and ψ angles of residues Arg3 (i+1) and Gly4 (i+2) are less than 30° from the
ideal angles for the type-I β-turn structure.26 Another indicator of β-turn structure is that the
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distance from the Cα atom at residue i to the Cα atom at residue i+3 must be 7 Å or less.26
The Cα-Cα distance between Pro2 (i) and Gly5 (i+3) is 6.9 ± 0.2 Å, which confirms the
presence of a β-turn at the PRGG sequence (Figure 4b). The turn structure of the PRGG
sequence is stabilized by a hydrogen bond between the backbone carbonyl group of Pro2
and the amide proton of Gly 5 (3.1 ± 0.3 Å) (Figure 4b), which suggests that the PRGG
motif in this peptide has a closed type-I β-turn conformation. The involvement of the Gly5
amide proton in hydrogen bonding is also indicated by the small value of the Gly5
temperature coefficient (−3.9 ppb/K) (Figure 5).
The MD simulation result did not confirm the presence of a type-I β-turn structure at the
GSVC sequence. The simulated (φ°, ψ°) angles of Ser6 (i+1) and Val7 (i+2) were (−148.2 ±
6.9°, 99.7 ± 6.4°) and (−144.6 ± 8.5°, −56.5 ± 7.0°), respectively. These values fall outside
the 30° deviation limit from the ideal values of φ and ψ angles of (i+1) and (i+2) residues for
the type-I β-turn structure.26 Visual observation of the ensemble of 10 structures from the
last 500 ps trajectories of the MD simulation showed no β-turn structure on the GSVC
sequence. However, a “turn-like” structure could be found at GSVCC sequence (Figure 4).
This turn-like structure involves five residues and is stabilized by a hydrogen bond between
the backbone carbonyl of Gly5 and the amide proton of Cys1 with a distance of 2.2 ± 0.3 Å.
Meanwhile, the Cα-Cα distance between Gly5 and Cys1 is 6.4 ± 0.4 Å, which is close to the
ideal Cα-Cα distance for type-I (6.31 Å) and type-II (6.26 Å) α-turns.30 Since the GSVCC
sequence is stabilized by a hydrogen bond and the Cα-Cα distance between Gly5 and Cys1
falls within the ideal Cα-Cα distance for a type-I or type-II α-turn structure, one might think
that the GSVCC sequence adopts these two types of α-turn structure. However, simulated φ
and ψ angles of GSVCC residues fall outside the 30° deviation limit from the ideal φ and ψ
angles for type-I or type-II α-turn structure.30 The high 3JNH-HCα coupling constant values
of Ser6 and Val7 suggests that the “turn-like” structure at GSVCC residues does not belong
to the α-turn structure. It is possible that the “turn-like” structure around residues Gly5-Ser6-
Val7-Cys8-Cys1 was randomly formed due to the side-chain cyclization between Cys1 and
Cys8. Therefore, the cyclo(1,8)-CPRGGSVC has adopted the type-I β-turn conformation at
the PRGG sequence and a “turn-like” structure at the GSVCC sequence.
Hydrogen Bonding Analysis of Amide Protons
In peptides, the amide proton chemical shifts are sensitive to temperature changes. The
amide protons involved in intramolecular hydrogen bonding are less sensitive to temperature
changes than amide protons that are solvent-accessed and not involved in intramolecular
hydrogen bonding network. The involvement of amide protons in hydrogen bonding can be
measured by calculating the temperature coefficient (Δδ/ΔT), which is the slope of amide
proton chemical shift changes over different temperatures.31 Small values of Δδ/ΔT (−3
ppb/K or less) indicate amide protons that are involved in intramolecular hydrogen bonding
and less exposed to the solvent. On the other hand, high values of Δδ/ΔT (−5 ppb/K or
more) suggest amide protons that are more exposed to the solvent.32
Our result indicates that Gly4 and Gly5 may have more involvement in intramolecular
hydrogen bonding than the other residues (Figure 5). The Δδ/ΔT values of Gly4 and Gly5
are −3.6 ppb/K and −3.9 ppb/K, respectively. The Δδ/ΔT values of the other residues are
(ppb/K): −14.0 (Arg3), −8.3 (Ser6), −6.7 (Val7), and −8.7 (Cys8). This suggests that there
are two possible intermolecular hydrogen bonds that involve the amide protons of Gly4 and
Gly5. The backbone carbonyl groups that might form hydrogen bonds with Gly4 or Gly5
can be determined by observing the three-dimensional structure of the peptide determined
by ROE-restraint molecular dynamics simulation.
Interestingly, the three-dimensional structure of the peptide shows two intramolecular
hydrogen bonds between the backbone carbonyl group of Pro2 and the amide protons of
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Gly4 and Gly5 (Figure 4b). The first hydrogen bond between Pro2 and Gly5 is responsible
for the stability of the β-turn of the PRGG motif as mentioned before. The second hydrogen
bond between Pro2 and Gly4 (Pro2 CO – Gly4 NH = 2.9 ± 0.4 Å) is suggested to strengthen
the rigidity of the β-turn conformation at the PRGG sequence.
DISCUSSION
We have shown that cyclo-CPRGGSVC is a good inhibitor of heterotypic T-cell adhesion.
27 The unique type-I β-structure at the PRGG sequence and a “turn-like” random coil
structure at the GSVCC sequence may contribute to its biological activity. This peptide is
the result of a reduction in the size of cIBR (cyclo(1,12)-PenPRGGSVLVTGC) peptide to
pinpoint the essential residues that play an active role in the biological activity of the cIBR
peptide.27 Cyclo(1,8)-CPRGGSVC was found to have slightly better activity than the parent
cIBR peptide in inhibiting heterotypic T-cell adhesion.27 This supports our previous
hypothesis that the PRGG motif is vital for the function of both cyclo(1,8)-CPRGGSVC and
cIBR peptide.22,25 It is interesting to find that the PRGG motif in cyclo(1,8)-CPRGGSVC
peptide maintains the type-I β-turn structure similar to that in the parent cIBR peptide. The
cIBR peptide has three consecutive turns: a type-I or type-II β-turn at Pro2-Arg3-Gly4-Gly5,
a type-I β-turn at Gly5-Ser6-Val7-Leu8, and a type-I β-turn at Val9-Thr10-Gly11-Cys12.25
It is noteworthy to mention that the β-turn structure of the PRGG motif in cyclo(1,8)-
CPRGGSVC and cIBR peptides, both of whose sequences were derived from the parent
molecule ICAM-1 receptor, is structurally similar to the β-turn structure of the Pro12-
Arg13-Gly14-Gly15 region of ICAM-1.25
Why is the PRGG motif so important? We have shown that the cIBR peptide binds to the
MIDAS (metal-ion dependent adhesion site) and L-site (allosteric site) of the LFA-1 I-
domain.23,24 The crystal structure of LFA-1/ICAM-1 complex shows that MIDAS is
located at the interface between two receptors;33 therefore, the binding of cIBR to MIDAS
may directly disrupt the LFA-1/ICAM-1 interaction. However, the mechanism of inhibition
of T-cell adhesion by cIBR that binds to L-site is not straightforward. We have shown that
the cIBR peptide binds to the L-site by extending the Gly5 to Gly11 residues to the
hydrophobic pocket of the L-site, while the Arg3 side chain of cIBR hinders the movement
of the α7 helix of the LFA-1 I-domain.27 Molecular dynamics simulation of LFA-1
complexed with lovastatin suggests that the binding of small molecules to the hydrophobic
pocket of the L-site greatly reduces the free movement of α7 helix that is vital for LFA-1
functions;34 therefore, inhibition of this movement may enable the LFA-1 receptor to bind
to ICAM-1 receptor. Meanwhile, the results of our initial fluorescence binding study results
suggest that the cyclo(1,8)-CPRGGSVC peptide also binds to the LFA-1 I-domain (data not
shown). The computational docking study shows an interesting feature of how the
cyclo(1,8)-CPRGGSVC peptide can inhibit the interaction of LFA-1 to ICAM-1. The Arg3
side chain interacts with the Lys305 residue that is located at the α7 helix of the LFA-1 I-
domain.27 These results suggest that Arg3 in cIBR and cyclo(1,8)-CPRGGSVC peptides
plays an important role in inhibiting the binding of LFA-1 to ICAM-1 by reducing the
motion of the α7 helix region.
In conclusion, we have shown that the cyclo(1,8)-CPRGGSVC peptide maintains the β-turn
conformation at the PRGG motif similar to its parent peptide, cIBR. Reducing the size of a
twelve-residue-long cIBR peptide to the eight-residue-long cyclo(1,8)-CPRGGSVC peptide
does not compromise the biological activity or the structure of the PRGG motif of the
peptide. With smaller size and less hydrophobicity, cyclo(1,8)-CPRGGSVC peptide is a
good candidate to be conjugated to drug compounds and can be used in targeted drug
delivery. The structurally well-conserved PRGG motif may be used in a peptidomimetic
approach to search for a better LFA-1/ICAM-1 inhibitor.
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Cyclo(1,8)-CPRGGSVC was synthesized by standard Fmoc solid phase peptide chemistry
on Fmoc-L-Cys(Trt)-PAL-PEG-PS resin (Applied Biosystems, Foster City, CA) using the
automated peptide synthesizer (PerSeptive Biosystems, Framingham, MA). All couplings
were carried out in DMF using HATU/DIEA as activator and 20% piperidine as deblocking
solution. Upon completion of the synthesis, the peptide was cleaved from the resin using a
cleavage mixture (reagent B) consisting of 95% trifluroacetic acid (TFA), 0.5% thioanisole,
0.3% ethanedithiol, and 0.2% anisole for 2 h at room temperature under nitrogen blanket.
Then, the mixture of resin and reagent B was filtered and the filtrate was added into cold
ether to yield a white precipitate of the crude peptide. The peptide was purified using semi-
preparative HPLC on a C-18 reverse phase column (Varian, Palo Alto, CA). Cyclization of
the pure linear peptide was accomplished by air oxidation in ammonium bicarbonate buffer
(0.05 M, pH 8.5) overnight in high dilution (0.06 mM). After cyclization, the peptide
solution was concentrated using a rotary evaporator to 10 mL followed by lyophilization.
The lyophilized powder containing peptide (10%) and ammonium bicarbonate (90%) was
then purified on semi-preparative HPLC using a C-18 column. The pure fractions of the
peptide were pooled and lyophilized. The molecular weight of the peptide was determined
by MALDI-TOF mass spectrometry.
NMR Spectroscopy
Two-dimensional NMR experiments were carried out on a Bruker Avance spectrometer
operating at 800 MHz for protons. The temperature dependence of the amide proton
chemical shifts was determined by one-dimensional proton NMR experiments between 298
and 323 K on a 400 MHz Bruker Avance spectrometer. Cyclo(1,8)-CPRGGSVC peptide (5
mg) was dissolved in 900 μL phosphate buffer (pH 5.0, 20 mM) and 100 μL D2O. Sodium
3-(trimethylsilyl)-1-propiosulfonic acid (DSS) was used as an internal reference for
chemical shift calibration in ROESY and TOCSY experiments. Meanwhile,
tetramethylsilane (TMS) was used for an internal standard in temperature dependence one-
dimensional NMR experiments. The 3JNH-HCα scalar coupling constants were calculated
from the backbone amide region of F1 row of ROESY spectrum using Karplus equation:35
Total correlation spectroscopy (TOCSY) and rotating-frame nuclear Overhauser
enhancement spectroscopy (ROESY) experiments were carried out by presaturation of water
during relaxation delay. Proton resonance assignments and spin system identification were
made using a TOCSY spectrum with mixing time of 62 ms. ROE assignments and
identification of sequential ROE connectivities were made using ROESY spectra with
mixing times of 200 ms. The ROE cross-peak volumes were classified as strong, medium,
and weak, and they were correlated to distances of dNα(i, i), dαN(i ,i+1), and dNN(i, i+1) for
which the upper limits were assigned as 2.4, 3.5, and 5.0 Å, respectively. Spectra
visualization was performed using CARA (Institute of Molecular Biology and Biophysics,
ETH Zurich, Switzrland) and MestReNova (Mestrelab Research S.L., Spain) softwares.
Molecular Dynamics Simulation
NMR-restraint molecular dynamics simulation was performed in MOE (Molecular
Operation Environment) software (Chemical Computing Group, Quebec, Canada) using
AMBER99 force field. The potential energy terms for AMBER99 force field is expressed in
an equation below:36
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where the total potential energy is the sum of bond stretching, angle bending, torsional
angle, van der Waals, and electrostatic energies. ROE distance restraints were applied with
upper limits of 2.8, 3.5, and 5.0 Å for strong, medium, and weak ROE peaks, respectively. A
peptide bond (ω) dihedral angle restraint of 180 ± 10° was applied to keep all peptide bond
as trans, except for Cys1-Pro2 peptide bond since the ROESY spectrum does not show the
presence of dαα cross-peak between Cys1 and Pro2 as an indicator of cis X-Pro, and also the
dαδ cross-peak between Cys1 and Pro2 as an indicator of trans XPro. A constant force of 10
kcal/mol.Å was applied. The starting structure was simulated at high temperature (600 K)
and NPT (constant pressure) in vacuo using dielectric constants of 1 and 80 for 30 ps to
relax the structure. The final structure was then soaked in a waterbox (with periodic system)
and was simulated at 300 K for 1000 ps (NPT), time-step of 0.1 fs, temperature and pressure
response of 0.1, respectively. Data were collected every 1 ps. The stability of the simulated
molecule was monitored by observing the backbone RMSD values. The RMSD values of
the last 500 ps of molecular dynamics simulation showed equilibrium condition with lesser
fluctuation compared to the first 500 ps of molecular dynamics simulation. The trajectories
from the last 500 ps of molecular dynamics simulation were taken for analysis. The
following criteria were used to determine the best fit solution conformation of peptide: (i)
the proton should have an interproton distance < 0.5 Ǻ compared to the upper boundaries of
distances from the ROE restraint; (ii) the conformation had φ angles within 30° of the
calculated φ derived from 3JNH-HCα.25
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(a) Fingerprint region of TOCSY spectrum of cyclo(1,8)-CPRGGSVC peptide. (b) NH-αH
region of ROESY spectrum of cyclo(1,8)-CPRGGSVC peptide superimposed with the
fingerprint region of TOCSY spectrum. The “backbone walk” of the ROESY/TOCSY
spectrum used to determine the sequence of the peptide is shown by the sequential numbers.
(c) NH-NH region of ROESY spectrum of cyclo(1,8)-CPRGGSVC peptide showing dNN(i, i
+1) cross-peaks
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Chemical shift indices (CSI, above the line) and summary of the inter-residue ROE effects
among the backbone NH, αH, and βH (below). The CSI values were equal to 0 or were not
calculated for amino acid residues with empty squares. The ROE intensities are reflected by
the thickness of the lines.
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One-dimensional NMR spectrum taken from F2 row of ROESY spectrum of cyclo(1,8)-
CPRGGSVC peptide. The value of 3JNH-HCα was taken from amide proton peaks on this
spectrum. The peak splitting is marked (d = doublet, t = triplet).
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Stereo-view of superimposed conformations of 10 structures taken from the last 500 ps
molecular dynamics trajectories (a). The trajectory with lowest energy was taken for clarity
(b). The hydrogen bonds between the backbone carbonyl group of Pro2 and amide protons
of Gly4 and Gly5 are shown by yellow dashed lines. The distance between Cα of Pro2 and
Cα of Gly5 is shown by an orange dashed line. The distance between Cα of Cys1 and Cα of
Pro2 is shown by a turquoise dashed line.
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Chemical shifts of amide protons of cyclo(1,8)-CPRGGSVC peptide at different
temperatures. The slope of the curve (Δδ/ΔT) is the temperature coefficient of the amide
proton.
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Table 2
Scalar coupling constant (3JNHαH), calculated φ and simulated dihedral angles (φ and ψ) of cyclo(1,8)-
CPRGGSVC peptide.
Residue 3JNHαH (Hz) Calculated φ (deg.) Structure (500–1000 ps)
φ (deg.) ψ (deg.)
Cys1 −66.5
Pro2 −78.0 163.2
Arg3 6.65 48.5, 71.5, −79.46, −160.54 −88.6 −24.8
Gly4 5.48 30, 90, −70.28, −169.72 −72.1 15.2
Gly5 5.67 87.8, 242.2, −71.75, −168.25 171.7, −169.6 167.4, −174.7
Ser6 7.83 −89.25, −150.75 −148.2 99.7
Val7 8.61 −96.98, −143.02 −144.6 −56.5
Cys8 6.26 79.61, 40.39, −76.32, −163,68 −95.1
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Table 3
Interproton distances, energy, and geometry analyses of simulated cyclo(1,8)-CPRGGSVC peptide. The
values of RMSD (root-mean square deviation) indicate how far the peptide NMR ensemble structures deviate
from the lowest energy structure.









Potential energy component Average potential energy for NMR ensemble structures (kcal/mol) S.D. (±)
Bond stretching 19.3 2.7
Angle bending 84.9 4.5
Improper torsion 6.4 1.5
Torsional angle 87.2 4.0
van der Waals 12.3 4.4
Electrostatic −303.3 3.5
Total −93.2 9.5
 RMSD (backbone) 0.308
RMSD (heavy atoms) 0.53
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